Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Erenumab · Aimovig, AMG-334

Monoclonal antibody · Antagonist of calcitonin gene-related peptide receptor (CALCRL) · developed by Amgen

Approved FDA, May 2018
AMGN Developer
1 Registered trials

What is Erenumab?

Erenumab-aooe is a human IgG2 monoclonal antibody that binds to and antagonizes the calcitonin gene-related peptide receptor.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Aimovig, AMG-334
Drug type
Monoclonal antibody
Targets
calcitonin gene-related peptide receptor (CALCRL)
Mechanism
Antagonist of calcitonin gene-related peptide receptor (CALCRL)
Therapy area
Neurology
Developer
Amgen Inc (AMGN)
FDA status
Approved as Aimovig (May 17, 2018), BLA761077 · FDA label
UNII
I5I8VB78VT

✅ FDA-approved uses

From the indications section of the FDA label (version of Jul 14, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03836040 Phase 3 Migraine Active not recruiting AMGN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Migraine

More from Amgen

Apremilast FDA approved Blinatumomab FDA approved Carfilzomib FDA approved Denosumab FDA approved Evolocumab FDA approved Pegloticase FDA approved Prednisone FDA approved Romiplostim FDA approved Romosozumab FDA approved Sotorasib FDA approved Tarlatamab FDA approved ABP 692 Phase 3

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the AMGN page.

Follow AMGN, the company behind Erenumab

See AMGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AMGN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.